Elusys Therapeutics, Inc.
about us technology product pipeline news&events careers
Elusys Overview Leadership Biodefense Corporate Fact Sheet
Executive Team Board of  Directors Scientific Advisory Board
Technology Heteropolymer Antibodies CR1 Vaccines Publications
Overview Process Animation
Antibody Heteropolymers Antigen Heteropolymers Anthrax Antibody
Pipeline Anthim Anthrax Antibody Staph A HP - ETI-211 Candida HP CR1 Vaccines
Press Releases Presentations
Our Values Working at Elusys Open Positions Benefits Location

NEWS & EVENTS

PRESS RELEASES 2006

2007   2006   2005   2004

 

December 13th, 2006


Elusys and U.S. Army Extend Biodefense Collaboration

 

October 16th, 2006

 

Elusys Announces fall 2006 conference schedule

 

September 28th, 2006

Elusys Presents Positive Data on Anthrax Therapeutic at ICAAC

 

July 13th, 2006

 

 

Elusys Therapeutics Completes $23 Million Series D Venture Financing

 

June 21st, 2006

 

 

Elusys' Anthrax Therapeutic, Anthim™, Granted FDA Orphan Drug Designation

 

April 20th, 2006

Elusys Enters into Infectious Disease License and Collaboration Agreement with Medimmune, Inc.

 

march 29th, 2006

Elusys Therapeutics Successfully Completes Human Clinical Study of Anthrax Therapeutic, Anthim™

 

february 16th, 2006

Elusys’ Anthrax Drug, Anthim™, Superior to Antibiotic as a Post-Exposure Monotherapy

 

february 13th, 2006

Elusys to Present New Post Exposure Efficacy Data for Anthrax Therapeutic, Anthim™, at ASM Bio Defense Research Meeting

 

january 24th, 2006

 

 

 

Elusys Therapeutics’ CEO to Present at Anti-Infectives Industry Summit

 

 

 

 

 

 

 

  • Copyright© 2008 Elusys Therapeutics, Inc. All Rights Reserved.
  • contact us
  • site map
  • careers